IP Library › Granted Patent US 11,730,719
Granted Patent B2
US 11,730,719 · App. 17/591,108 · Granted Aug 22, 2023

Pharmaceutical composition

Inventors: Shin Sugimoto (Fuji, JP); Akito Minamizono (Fuji, JP)
Assignee: KOWA COMPANY, LTD.
A61K31/423
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,719
App. No.
17/591,108
Granted
Aug 22, 2023
Kind
B2
Abstract

Provided is a pharmaceutical composition which contains pemafibrate, a salt thereof or a solvate thereof and has excellent stability. A pharmaceutical composition is provided containing pemafibrate, a salt thereof or a solvate thereof and having a moisture content of 2.4 mass % or less.

Claims (8)

1. A pharmaceutical composition comprising a pemafibrate crystal, wherein the pemafibrate crystal has a peak at one or more diffraction angles (2θ) selected from the group consisting of around 7.3±0.2°, around 14.6±0.2°, around 15.3±0.2°, around 16.2±0.2°, around 18.2±0.2°, around 18.9±0.2°, around 20.6±0.2°, around 21.5±0.2°, around 22.5±0.2° and around 24.1±0.2° in a powder X-ray diffraction pattern obtained by irradiation with Cu-Kα radiation.

2. The pharmaceutical composition according to claim 1 , wherein the pemafibrate crystal has peaks at diffraction angles (2θ) of around 14.6±0.2°, around 15.3±0.2°, around 20.6±0.2° and around 22.5±0.2° in a powder X-ray diffraction pattern obtained by irradiation with Cu-Kα radiation.

3. The pharmaceutical composition according to claim 1 , wherein the pemafibrate crystal has peaks at diffraction angles (2θ) of around 7.3±0.2°, around 14.6±0.2°, around 15.3±0.2°, around 16.2±0.2°, around 18.2±0.2°, around 18.9±0.2°, around 20.6±0.2°, around 21.5±0.2+, around 22.5±0.2° and around 24.1±0.2° in a powder X-ray diffraction pattern obtained by irradiation with Cu-Kα radiation.

4. The pharmaceutical composition according to claim 1 , wherein the pemafibrate crystal is a crystal having a melting point of 95 to 101° C.

5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a solid preparation.

6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a tablet, a capsule, a granule, a powder or a pill.

7. A pharmaceutical preparation obtained by storing the pharmaceutical composition according to claim 1 in a tight package.

8. A pharmaceutical preparation according to claim 7 , wherein the tight package is one or more selected from the group consisting of a bottle package, an SP package, a PTP package, a pillow package and a stick package.

Priority Claims (1)
JP 2017-129306 · Jun 30, 2017 · national
Continuity (2)
Continuation 16627178
Related Publication 20220151996A1 · May 19, 2022